ChargePoint Technology named as a finalist for prestigious business award
ChargePoint Technology has been named as a finalist in the Liverpool Echo Regional Business Awards, in what judges have described as “another outstanding year.”
The annual awards ceremony, sponsored by KPMG, DLA Piper and Lloyds Bank, takes place at St George’s Hall on June 23rd and will see ChargePoint in the running for the accolade of Manufacturer of the Year.
The company is up against Jaguar Land Rover and Flowtech Fluid Powder.
Chris Eccles, Managing Director of ChargePoint Technology said: “We are absolutely delighted to have been named as a finalist in these prestigious awards and this recognition is another boost for the business and all the staff.
“We are a growing business operating in a highly risk averse sector and we have worked extremely hard to get to where we are today. We remain as ambitious as ever to grow the business further and make more inroads into overseas markets with our innovative products, designed and manufactured here in Liverpool, a fact of which we are very proud.”
ChargePoint Technology supplies precision containment valves to some of the biggest pharmaceutical names across the globe for the development of medicines and vaccines from their premises in Speke which is home to the largest cluster of biologic manufacturing in Europe.
In the last year the company has taken to market the AseptiSafe bio valve, which creates a sterile area the size of a dinner plate and reduces the need for the large scale clean rooms and isolators.
The device also speeds up production and protects operators from hazardous products.
ChargePoint Technology are the only company which uses a patented hydrogen peroxide decontamination cycle in their valve to destroy contaminants and bacteria, which makes it the only bio-decontamination valve in history.
The company has also developed a wireless monitoring platform, called VERIFI, that communicates vital equipment performance data to help maximise the reliability, safety and profitability of the production facility and its final drug product.